Coulibaly B et al., 2014-09-28: Phase IIb randomised trial in 221 Burkinabé children adding methylene blue to artesunate-amodiaquine for three days. Gametocyte prevalence fell significantly, but haemoglobin was significantly lower and vomiting more frequent in the MB arm.
It was significantly lower in the AS-AQ-MB than in the AS-AQ group on day 7 of follow-up (microscopy, 1.2% vs 8.9% [P < .05]; QT-NASBA, 36.7% vs 63.3% [P < .001]).
Abstract
Coulibaly B et al., 2014-09-28: Phase IIb randomised trial in 221 Burkinabé children adding methylene blue to artesunate-amodiaquine for three days. Gametocyte prevalence fell significantly, but haemoglobin was significantly lower and vomiting more frequent in the MB arm. Study type: randomised controlled phase IIb trial, NCT01407887. N=221 children 6-59 months, Burkina Faso. MB added to 3 days of artesunate-amodiaquine; per-day mg/kg not in the abstract (the programme's 2019 trial used 15 mg/kg/day x 3 days). Comparator: artesunate-amodiaquine. Primary endpoint: gametocyte prevalence by microscopy and QT-NASBA. Harms: significantly lower haemoglobin at days 2 and 7, more vomiting. Funder/COI not stated in retrieved abstract record. Bearing deliberately mixed: transmission endpoint met, haematological safety signal present. Study type: randomized trial.
